08 Feb 2012
Their study suggests that the novel RWD-domain containing protein RSUME is a new and important player in pituitary tumour pathogenesis. It is overexpressed in human pituitary adenomas and critically regulates HIF-1α expression and VEGF-A production under hypoxia. Through supporting pituitary tumour neovascularisation, RSUME might be critically involved in pituitary adenoma progression. Therefore, it represents a new putative therapeutic target for the development of novel anti-angiogenic treatment concepts of human pituitary tumours. Shan et al. (2012) Endocrine-Related Cancer 19 13-27.
Read the full article at DOI: 10.1530/ERC-11-0211.
New Awards Committee Chair
29 Jan 2025
Society for Endocrinology endorses landmark guidelines for childhood pituitary tumour care
29 Jan 2025
Announcing the Winners of the SfE Emerging Researcher Lectures 2025
23 Jan 2025
Congratulations to the awardees of our third round of 2024 grants
22 Jan 2025